Research programme: immune tolerance-inducing therapeutics - Anokion

Drug Profile

Research programme: immune tolerance-inducing therapeutics - Anokion

Alternative Names: Autoimmune disease therapeutics - Anokion; Cancer therapeutics - Anokion; Diabetes therapeutic - Anokion; Immune-masked protein theraputics - Anokion; Tolerogenic asparaginase - Anokion

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anokion
  • Class Antigens; Peptides; Proteins
  • Mechanism of Action Antigen-presenting-cell-modulators; Immunomodulators; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer
  • No development reported Gout

Most Recent Events

  • 09 Jan 2017 Anokion and Celgene enter into research collaboration for immune tolerance-inducing therapeutics for Autoimmune disorders
  • 16 Jul 2016 No recent reports of development identified for research development in Gout in Switzerland (IV)
  • 05 May 2014 Research programme: immune tolerance-inducing therapeutics - Anokion is available for licensing as of 05 May 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top